Skip to content
Schrödinger logo — Transforming drug discovery and materials research

Schrödinger

Transforming drug discovery and materials research

Founded 1990 United States New York, United States 978 employees IPO Total: $871.40M Biotechnology, Enterprise Software +1

General Information

Company Name Schrödinger
Founded Year 1990
Location United States New York, United States
Employees 978
Industries Biotechnology, Enterprise Software, Pharmaceutical
Funding Stage IPO
Business Model B2B, SaaS, B2C
Revenue Model Subscription, Licensing, Service Fee
Social

BounceWatch is an independent company data service, not affiliated with Schrödinger. To contact Schrödinger, visit schrodinger.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Schrödinger compare?

A PDF of Schrödinger and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Schrödinger soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

Feature Release Nov 04, 2026

Schrödinger released its 2026-4 software version featuring new molecular design capabilities and usability updates.

Certification Nov 03, 2026

Schrödinger has officially achieved ISO/IEC 27001:2022 certification for its Information Security Management System.

Event Participation Oct 30, 2026

Schrödinger is hosting its Frontiers in Digital Chemistry event series in Japan.

AI Insight

Bounce Watch AI
1 week ago

Schrödinger is demonstrating sustained growth and strategic development through continuous innovation, marked by its latest 2026-4 software release that enhances molecular design capabilities. Concurrently, the company is strengthening its market position by expanding its international presence through events in Japan and boosting operational credibility with ISO/IEC 27001:2022 certification, critical for securing enterprise and biopharmaceutical clients.

Signal Types
Product Launch Expansion Certification
Strategic Labels
Product Innovation Market Expansion Operational Excellence
Next Move: Expansion
·
Impact: 8/10
·
Ideal For: Public Market Growth Investors — Tech & Life Sciences

About Schrödinger

Schrödinger, founded in 1990, is a frontrunner in the realms of Biotechnology, Enterprise Software, and Pharmaceutical industries. Headquartered in the United States, the company leverages its cutting-edge computational platform to advance drug discovery and materials research.

The firm's platform supports the research initiatives of biopharmaceutical companies, academic institutions, and government laboratories across over 70 countries, emphasizing a commitment to scientific innovation and cultivating top-tier talent. Moreover, Schrödinger operates its own drug discovery programs in diverse therapeutic areas, both independently and in collaboration with other entities.

The company recently received a $10.00 million grant investment from the Bill & Melinda Gates Foundation on 01 July 2024, signaling strong confidence in its potential to revolutionize its field. Vigilance against recruitment scams underscores Schrödinger's focus on integrity and trust in its interactions.

Business keywords: Computational Platform, Drug Discovery, Biopharmaceutical Research, Materials Research, Academic Partnerships, Government Collaborations, Therapeutic Areas, Scientific Investment, Technology Development, Collaborative Programs, Research Facilitation, Industrial Solutions, Talent Development, Recruitment Security

Services & Products

Software development for molecular discovery
Predictive computational platform
Drug discovery solutions
Materials science solutions
Clinical program management
Collaborative and proprietary drug discovery programs

Target Customers

Biotech companies Pharmaceutical companies Academics Research institutions Chemical manufacturers Consumer packaged goods industries Oil and gas industries

Funding Rounds & Investors (10)

View All
Funding Stage Amount Investors Lead Investors Date
Grant $10.00M 1
Bill & Melinda Gates Foundation
01 Jul 2024
Grant $4.90M 1
Bill & Melinda Gates Foundation
01 Nov 2021
Post-IPO Equity $346.50M -
01 Aug 2020
IPO $232.00M -
01 Feb 2020
Series F $110.00M 4
Bill & Melinda Gates Foundation, Invus +2
01 May 2019
Late VC $85.00M 4
Qiming Venture Partners, Bill & Melinda Gates Foundation +2
01 Jan 2019
Growth Equity VC $22.00M 1
Becker Ventures
01 Jun 2015
Growth Equity VC $20.00M 1
Bill Gates
01 Dec 2012
Late VC $10.00M 2
Bill Gates, Cascade Investment
01 Apr 2010
Series A $31.00M -
01 Mar 2002

Schrödinger Alternatives & Competitors

View All Alternatives
Schrödinger vs

Together, We Create Healthier Lives

IPO
14325 employees
Biotechnology, Health Care
Schrödinger vs
Erasca, Inc.
Erasca, Inc. United States

Our mission at Erasca is embedded in our name: To erase cancer.

Post-IPO Equity
114 employees
Biotechnology, Life Sciences
Schrödinger vs

Scientific Research by Artificially Intelligent Agents

20 employees
Biotechnology, Pharmaceutical

FAQ About Schrödinger

Transforming drug discovery and materials research
Schrödinger was founded in 1990.
Schrödinger is headquartered in New York, United States.
Schrödinger operates in Biotechnology, Enterprise Software and Pharmaceutical. Its work centres on Computational Platform, Drug Discovery, Biopharmaceutical Research and Materials Research. Its customers include Biotech companies, Pharmaceutical companies and Academics.
Schrödinger has a B2B, SaaS and B2C business model. Its revenue comes from Subscription, Licensing and Service Fee.
Schrödinger has approximately 978 employees.
Schrödinger has completed 10 funding rounds, raising a total of $871.40M. The latest funding stage is IPO.
Schrödinger offers: Software development for molecular discovery, Predictive computational platform, Drug discovery solutions, Materials science solutions, Clinical program management, Collaborative and proprietary drug discovery programs.
Top alternatives and competitors to Schrödinger include Charles River Laboratories, Erasca, Inc., SyntheticGestalt, Antiverse, Astex Pharmaceuticals . These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Schrödinger and Charles River Laboratories are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Schrödinger, https://www.bouncewatch.com/company/schrodinger, updated 8 November 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout